Su1083 SMALL INTESTINAL BACTERIAL OVERGROWTH AND NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Karn Wijarnpreecha, Susan Lou, Kanramon Watthanasuntorn, Paul T. Kroner, Wisit Cheungpasitporn, Frank Lukens, Surakit Pungpapong, Andrew Keaveny, Patompong Ungprasert Background/Objectives: Recent studies have suggested that small intestinal bacterial overgrowth (SIBO) could be a predisposing factor for nonalcoholic fatty liver disease (NAFLD) although the results were inconsistent. This systematic review and meta-analysis was conducted with the aim to summarize all available data. Methods: A comprehensive literature review was conducted utilizing MEDLINE and Embase databases through September 2018 to identify all studies that compared the risk of NAFLD among patients with SIBO versus those without SIBO. Effect estimates from each study were extracted and combined together using the random-effect, generic inverse variance method of DerSimonian and Laird. Results: A total of ten studies with 1,093 participants fulfilled the eligibility criteria and were included in the meta-analysis. The risk of NAFLD among patients with SIBO was significantly higher than those without SIBO with the pooled odds ratio of 3.82 (95% confidence interval, 1.93- 7.59; I 2 65%). We performed a sensitivity analysis by excluding studies that included only patients with NASH into their studies to avoid selection bias of only patients with more severe disease as NASH is at the more advanced spectrum of all patients with NAFLD. Exclusion of those studies did not significantly alter the result of the meta-analysis with the new pooled OR of 3.07 (95% CI, 1.25 - 7.53; I 2 75%). Conclusions: A significantly increased risk of NAFLD among patients with SIBO was observed in this meta-analysis. Increase in endotoxin and ethanol production, choline deficiency and increased intestinal permeability could be the links behind this association. Forest plot of all studies Su1084 NO SIGNIFICANT IMPACT OF FRUCTOSE CONSUMPTION ON GUT MICROBIOTA COMPOSITION IN A GERMAN COHORT OF PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) Kathrin Heinzer, Sonja Lang, Farowski Fedja, Hilmar Wisplinghoff, Maria Vehreschild, Marcin Krawczyk, Frank Lammert, Anna Martin, Angela Nowag, Anne Kretzschmar, Jens Herweg, Tobias Goeser, Hans-Michael Steffen, Münevver Demir Background and Aims: High fructose consumption has been suggested as major risk factor for the development and progression of NAFLD by increasing hepatic de novo lipogenesis, suppressing liver fat oxidation, and altering the gut microbiota. In this prospective cross- sectional study, we aimed to evaluate associations between bacterial gut microbiota composi- tion based on the level of fructose consumption in patients with biopsy-proven NAFLD. Patients and methods: Sixty-eight patients with biopsy-proven NAFLD (n=21 NAFL, n= 47 NASH) were enrolled, and 51 patients (75%) completed a food and activity diary over a period of 14 days. Nutrition facts of the patients' individual diets were calculated with Ebispro 2016 professional software. Based on their median fructose consumption, patients were divided into two groups: “low fructose” group (intake<15g/d) and “moderate to high fructose” group (intake ≥15g/d). Taxonomic profiling of stool samples from each patient was performed by 16S rRNA gene sequencing. Linear discriminant analysis (LDA) effect size (LEfSe) analysis was performed to detect differences in the bacterial composition of gut microbiota between both groups. Results: Mean age of analyzed study subjects (n=51) was 51.2±15.6 years, and 31% (n=21) were women. Median and mean fructose consumption were 15.1g/d (1.6-44.2 g/d, min-max) and 16 g/d (SD ±5.8), respectively. Thirty-two patients (63%) had a low fructose consumption (<15g/d) and 19 patients (37%) presented with moderate fructose intake (≥15g/d to 50g/d). Remarkably, none of the patients had a “high” fructose intake of more than 50g/d. Furthermore, the LEfSe analysis showed no significant differences in gut microbiota composition between both groups. Conclusions: The absence of high fructose consumption in this study suggests a lower dietary intake in German compared to North American NAFLD patients and may explain why the gut microbiota composition did not differ significantly between both study groups. If high fructose intake (>50g/d) is an essential prerequisite for intestinal dysbiosis, the pathogenic impact of fructose on NAFLD in Western Europe might be smaller than previously assumed. S-1271 AASLD Abstracts Su1085 ALTERATION IN GUT MICROBIOTA ASSOCIATED WITH HEPATITIS B AND NON-HEPATITIS VIRUS RELATED HEPATOCELLULAR CARCINOMA Qisha Liu, Fan Li, Yaoyao Zhuang, Jian Xu, Yewei Zhang, Xingyin Liu Background The onset of hepatocellular carcinoma (HCC) ranked fifth malignancies all over the world. Increasing evidences showed that the distribution of HCC was related to the incidence of chronic hepatitis B virus (HBV) infection and other factors. Recent studies demonstrated that gut dysbiosis plays an important role in liver diseases. However, the researches on gut microbiota of HBV and non-HBV non-HCV related HCC have not been reported. In this study, we investigated the differences between the gut microbiota of HBV related HCC (B-HCC) and non-HBV non-HCV related HCC (NBNC-HCC), finally found some potential bacteria, linking different pathological mechanism of both types of HCCs. Results We carried out 16S rRNA analyses in a cohort of 33 healthy controls, 35 individuals with B-HCC and 22 individuals with NBNC-HCC. We found that the species richness of fecal microbiota of B-HCC patients was much higher than other two groups. Interestingly, the feces of NBNC-HCC patients harbored more potential pro-inflammatory bacteria (Esche- richia-Shigella, Enterococcus) and reduced levels of Faecalibacterium, Ruminococcus, Rumi- noclostridium which results in decrease potential of anti-inflammatory short-chain fatty acids. The feces of NBNC-HCC patients had relatively fewer abundance of multiple biological pathways related to amino acid and glucose metabolism, but high level of transport and secretion in some types. However, the B-HCC patients had opposite results of bacterial composition and associated multiple biological pathways versus NBNC-HCC patients. Mean- while, we found that aberrant network of gut microbiota occurred differently in B-HCC and NBNC-HCC patients. Conclusions Our study indicated that B-HCC and NBNC-HCC patients showed differential abundance of bacteria involved in different functions or biological pathways. We suggested the modification of specific gut microbiota may provide the thera- peutic benefit for B-HCC and NBNC-HCC. Different genera across healthy controls, HBV related HCC (B-HCC), and non-HBV non- HCV related HCC (NBNC-HCC). A. Heat map of the top 35 genera. P value < 0.050 by Wilcoxon rank sum test with light green star. Red in color presents Gram negative bacteria, blue in color presents Gram positive bacteria. B. Changes in intestinal microbiota and the possible relations to intestinal dysfunction, gut dysbiosis, and other complications in non-HBV non-HCV related HCC. C. Changes in intestinal microbiota and the possible relations to intestinal dysfunction, gut dysbiosis, and other complications in HBV related HCC. D. The relationship between 6 serologic indices (GST, AST, GGT, AFP, TBil, albumin) and top 35 genera is estimated by Spearman’s correlation analysis. *, P < 0.050; **, P < 0.010; ***, P < 0.001. AASLD Abstracts